AWA
CORT icon

Arkadios Wealth Advisors’s Corcept Therapeutics CORT Stock Holding History

Arkadios Wealth Advisors’s Portfolio CORT Stock Details CORT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$227K Buy
+2,609
New +$158K ﹤0.01% 1562
2024
Q3 		– Sell
-16,224
Closed -$527K – 939
2024
Q2 		$527K Sell
16,224
-1,003
-6% -$27.5K 0.04% 454
2024
Q1 		$434K Buy
+17,227
New +$407K 0.03% 416

Other funds holding CORT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ISL
Ingalls & Snyder LLC New York $3.66B AUM 57.76% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PA
Parallel Advisors San Francisco, California $6.56B AUM 32.24% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Arkadios Wealth Advisors's CORT Position: Q2 2026 in Review

Arkadios Wealth Advisors opened a new position in Corcept Therapeutics (CORT) in Q2 2026: 2,609 shares worth $227K. The stake represents ﹤0.01% of the portfolio and ranks #1562 among its holdings. This is a return to the name: Arkadios Wealth Advisors previously reported a position in CORT as recently as Q2 2024.

Arkadios Wealth Advisors first reported a position in CORT in Q1 2024 and has held it in 3 quarters since. The position peaked at $527K in Q2 2024. 423 funds tracked by Wall St. Rank hold CORT as of Q2 2026.

  • Arkadios Wealth Advisors held 2,609 shares of Corcept Therapeutics worth $227K as of Q2 2026.
  • Corcept Therapeutics was a new Arkadios Wealth Advisors position in Q2 2026.
  • Corcept Therapeutics made up ﹤0.01% of Arkadios Wealth Advisors's portfolio in Q2 2026, its #1562 holding.
  • Arkadios Wealth Advisors first reported a position in Corcept Therapeutics in Q1 2024 and has held it in 3 quarters since.
  • Arkadios Wealth Advisors's Corcept Therapeutics position peaked at $527K in Q2 2024.
  • 423 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q2 2026.

Based on Arkadios Wealth Advisors's 13F filing for Q2 2026, filed 10 Aug 2026.